Lepu Scientech Medical Technology (Shanghai) (HKG:2291) entered into a clinical trial service framework agreement, a purchase of parts framework agreement, a sale-of-products framework agreement, and an entrusted-products-related framework agreement with its controlling shareholder, Lepu Medical (SHE:300003), on Friday, a Monday Hong Kong bourse filing said.

The company and Lepu had previously entered into similar agreements in October 2022 which were going to expire by the end of the year, therefore the parties have renewed the agreements.

For the clinical trial agreement, Lepu Medical Group will provide clinical trial services for the company for another three years, ending on Dec. 31, 2027.

For the purchase of parts framework agreement, the group will be purchasing customized parts used in the production of congenital heart disease occluders and congenital heart disease occluder delivery systems, snares, LAA occluder systems, and biodegradable delivery systems from Lepu for another three years.

Under the sale of the products framework agreement, the group will sell the occluders and relative products to Lepu (Shanghai), Anhui Magete, and Lepu (India) for another three years.

Under the entrusted products-related framework agreement, the company agreed to purchase Lepu Medical's TAVR system upon its commercialization and will exclusively take care of the sales, distribution, and other matters for three years ending on Dec. 31, 2027. The agreement has a term of three years

Price (HKD): $16.16, Change: $-0.14, Percent Change: -0.86%